Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2008

View Archived Issues

Ranbaxy patents novel muscarinic receptor antagonists

New analgesic agents imparted in recent patent literature

Novel treatments for dermatological disorders disclosed in recent patents

Sanofi pasteur's acquisition of Acambis completed

Manageable levels of neuropathy in breast cancer patients receiving eribulin

Novel GIP antagonist shows efficacy in preclinical models of obesity and type 2 diabetes

Positive phase I interim results of XOMA-052 in type 2 diabetes

Almirall receives payment from Forest as part of aclidinium collaboration

Arana Therapeutics provides update on recent pipeline activity

Safety results presented at the WSC from the V-10153 stroke thrombolysis trial

LAU-0901 neuroprotective in a rat model of focal cerebral ischemia

BioMS receives milestone payment based on positive review of MAESTRO-01 trial

MAP completes enrollment in phase III nebulized budesonide trial in children with asthma

ChemBridge enters into new discovery alliance with AstraZeneca

Discovery Laboratories completes response to FDA approvable letter for Surfaxin

BIO-11006 shows promise as a COPD treatment

Dyax completes BLA for DX-88 in hereditary angioedema

Inspire requests SPA process for Prolacria for dry eye

Independent Data Safety Monitoring supports continuation of Iluvien trial

Cellerant Therapeutics receives contract for acute radiation syndrome treatment

CHMP issues positive opinion for olanzapine long-acting injection in schizophrenia

Concert commences phase I CTP-347 trial in healthy volunteers

FDA approves Nasacort AQ Nasal Spray for children with allergic rhinitis

ImClone starts enrollment in phase II IMC-A12 trial in advanced breast cancer

RegeneRx enrolls first subject in phase Ib RGN-352 trial

Xenome evaluates XEN-2174 in phase II trial in acute pain

Thallion enrolls first patient in phase II TLN-4601 trial; FDA approves trial in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...